{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:16:56Z","timestamp":1762899416452},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,9,1]]},"abstract":"<jats:p> PURPOSE: To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy. <\/jats:p><jats:p> PATIENTS AND METHODS: We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D. Anderson Cancer Center treated between 1989 and 1998 with HDCT and autologous or allogeneic hematopoietic transplantation. <\/jats:p><jats:p> RESULTS: A total of 36 patients were studied (29 received autologous transplantation, and seven received allogeneic transplantation). The overall survival rate at 3 years was 36% (95% confidence interval [CI], 23% to 59%), and the progression-free survival (PFS) rate was 28% (95% CI, 16% to 49%). The pretransplant serum lactate dehydrogenase level was the most important prognostic factor for both survival and PFS rates (P &lt; .001). A Pretransplant International Prognostic Index score of \u2264 1 indicated a superior survival rate (P = .036) but not an improved PFS rate. A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease. <\/jats:p><jats:p> CONCLUSION: Our results are comparable to the published data on HDCT in B-cell non-Hodgkin\u2019s lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients. Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation. <\/jats:p>","DOI":"10.1200\/jco.2001.19.17.3766","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:31:41Z","timestamp":1487921501000},"page":"3766-3770","source":"Crossref","is-referenced-by-count":121,"title":["Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas"],"prefix":"10.1200","volume":"19","author":[{"given":"Jose","family":"Rodriguez","sequence":"first","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Munsell","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Yazji","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje","family":"Andersson","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Gajewski","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Couriel","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando F.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa F.","family":"Khouri","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-094126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"R2-094126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R3-094126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.6.725"},{"key":"R4-094126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1426"},{"key":"R5-094126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1783"},{"key":"R6-094126","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057673"},{"key":"R7-094126","doi-asserted-by":"crossref","unstructured":"Melnyk  A,   Rodriguez  A,   Pugh  WC,  et al:  Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma.  Blood 89:  4511,1997-4520,","DOI":"10.1182\/blood.V89.12.4514"},{"key":"R8-094126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R9-094126","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058324"},{"key":"R10-094126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"R11-094126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401"},{"key":"R12-094126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.4.1243.bloodjournal8741243"},{"key":"R13-094126","unstructured":"Biron  P,   Droz  JP:   [Experience with non-Hodgkin\u2019s lymphoma].  Bull Cancer 82:  53S,1995-55S,     (suppl 1)"},{"key":"R14-094126","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89488-0"},{"key":"R15-094126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2324.2324"},{"key":"R16-094126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"R17-094126","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70470-6"},{"key":"R18-094126","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1261-1_10"},{"key":"R19-094126","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R20-094126","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"R21-094126","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.2.424.424"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.17.3766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:45:34Z","timestamp":1653515134000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.17.3766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,1]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2001,9,1]]}},"alternative-id":["10.1200\/JCO.2001.19.17.3766"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.17.3766","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,1]]}}}